Statement Regarding GAO Report on Drug Prices

Washington, D.C. (March 14, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement regarding the Government Accountability Office’s (GAO) report on drug prices:

“We are pleased the GAO appropriately took into account the facts about how the biopharmaceutical marketplace works in its analysis of prescription medicine pricing trends. The report’s key finding shows prices have been increasing at a rate of 2.6% annually, which is lower than overall medical inflation.

Survey of Physicians About Pharmaceutical and Biotech Research Company Activities and Information

PhRMA Statement on the Independent Payment Advisory Board

Washington, D.C. (January 31, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Wes Metheny issued the following statement today:

“We continue to have significant concerns about the overly broad powers of the unelected IPAB, which could enact sweeping Medicare changes without Congress’ oversight and which would not be subject to judicial or administrative review.

“We believe IPAB will result in access problems for Medicare beneficiaries. Therefore, IPAB in its current form must be repealed.

Sino-Phirda and PhRMA Sign Joint Cooperation Agreement

Washington, D.C. (November 19, 2010) — Following a two day conference in Washington, DC, the China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) today signed a cooperation framework that embodies the intent of the multi-national pharmaceutical companies and Chinese pharmaceutical companies to continue a regular dialogue that will facilitate the two organizations working together.

PhRMA Statement on the FDA Approving Biosimilars

Washington, D.C. (Nov. 3, 2010) – Pharmaceutical Research and Manufacturers of America (PhRMA) Associate Vice President for Scientific & Regulatory Affairs Marie A. Vodicka testified today at the Food and Drug Administration’s public hearing on federal implementation of the new biosimilars approval pathway.

PhRMA Statement Regarding Puerto Rico Law 154

Washington, D.C. (October 25, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President John Castellani [bio] released the following statement about Law 154, which was signed today in Puerto Rico:

PhRMA Urges Support for International Standards in Russian Medicines Law

Washington, D.C. (March 4, 2010) — As Russia embarks on legislative reforms to strengthen pharmaceutical regulation, the Pharmaceutical Research and Manufacturers of America’s (PhRMA) President of International Affairs Christopher A. Singer called on the Russian government to use the opportunity to align with international standards and obligations on clinical trial regulation and intellectual property rights.

The U.S. Prescription Drug Lifecycle

Innovator pharmaceutical companies produce medical advances through pioneering scientific work and large-scale investments which lead to new medicines and, over time, to generic copies that consumers use at low cost for many years.

PhRMA Statement on Senate Health Care Reform Bill

Washington, D.C. (November 19, 2009) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson released the following statement about the Senate health care reform bill:

“While we are still reviewing the Senate bill, we remain committed to do our part to make comprehensive health care reform a reality this year. We believe that all Americans should have access to high-quality, affordable health care coverage and services. If done in a smart way, health care reform will benefit patients, the economy and the future of America.

Global Partnerships


Subscribe to RSS - Access